Wegovy in Scotland: how access works and what your options are

Does Scotland have different NHS criteria for Wegovy than England?

Yes, and the difference matters. NHS England is rolling out tirzepatide and semaglutide through a phased, nationally published eligibility schedule tied to specific BMI thresholds and a list of qualifying conditions. Scotland takes a different approach. NHS Scotland commissions weight-management medicines, including semaglutide (Wegovy), primarily through specialist weight-management services, guided by SIGN 115, Scotland's own obesity management guideline. Eligibility is assessed on clinical need rather than a single published BMI cut-off in the same format England uses.

In practice this means a GP in Scotland may refer you to a specialist service, and that service decides whether Wegovy is appropriate for you based on your full clinical picture. Waiting times for those services are, in many areas, significant. NHS Inform Scotland notes that diabetes and weight-loss medicines are available through NHS Scotland, but acknowledges that access depends on referral pathways and local commissioning decisions. If you are trying to understand where Scotland stands relative to the English rollout, the short answer is that the frameworks differ, and your best starting point is a conversation with your GP about what your local health board commissions.

Lower BMI thresholds typically apply for people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds under UK clinical guidance, and this adjustment applies in Scotland as it does elsewhere.

What does NICE say, and does it apply in Scotland?

NICE is England and Wales's approval body. Its technology appraisal for semaglutide (Wegovy), TA875, recommends the medicine for adults with a BMI of 35 or above and at least one weight-related comorbidity, used for a maximum of two years within a specialist weight-management service. That recommendation is published by NICE and carries weight in clinical circles, but it does not automatically bind NHS Scotland. Scotland's medicines body, the Scottish Medicines Consortium, makes its own recommendations.

For practical purposes, the licensed eligibility criteria for Wegovy across the UK are set by the MHRA and reflected in the medicine's prescribing information: adults with a BMI of 30 or above, or 27 or above with a weight-related condition such as high blood pressure, type 2 diabetes, or obstructive sleep apnoea. A private prescriber anywhere in the UK assesses against that licensed criterion; NHS commissioners add their own access conditions on top of it. You can find the NICE appraisal of Wegovy (TA875) on the NICE website if you want to read the detail.

If you are comparing how access works in other parts of the UK, there is a separate overview of Wegovy access in England that covers the NHS England phased rollout in full.

How does private access to Wegovy in Scotland actually work?

Because Wegovy is a prescription medicine, accessing it privately means going through a regulated prescriber and a GPhC-registered pharmacy, wherever you live in the UK, Scotland included. There is no legal shortcut. An online pharmacy registered with the General Pharmaceutical Council can legally supply Wegovy to patients across Scotland following an independent prescriber's assessment. You do not need a GP referral for a private consultation, and there is no waiting list involved on the private side.

At nume, our GPhC-registered pharmacy (registration number 9012878, verifiable at the GPhC register) serves patients throughout Scotland. A GPhC-registered independent prescriber, not software, reviews your consultation the same day. Once approved, your treatment is dispensed and dispatched for free next-working-day delivery by DPD, tracked, in plain packaging. A quick check worth doing before using any online pharmacy: look it up on the GPhC register using the link above. If a pharmacy is not listed there, do not use it for a prescription medicine.

The cost context for private Wegovy is similar whether you are in Glasgow or Guildford. For a broader look at what private treatment involves, our Wegovy treatment overview covers the full picture, including what to expect at each stage. There is also a plain summary of weight-loss treatment options if you are still weighing up which medicine suits you.

What should people in Scotland know about Wegovy before they start?

Wegovy is semaglutide, a GLP-1 receptor agonist given as a once-weekly injection. Clinical trials published in the New England Journal of Medicine showed an average weight reduction of around 15% over 68 weeks at the 2.4mg maintenance dose, alongside a reduced-calorie diet and increased activity. The MHRA also approved a higher 7.2mg dose in early 2026, with trial results approaching 20% average weight loss; availability of specific dose formats is confirmed at the prescribing stage.

The most common side effects are gastrointestinal: nausea and loose stools are particularly frequent in the early weeks, usually settling as your system adjusts. Severe, persistent stomach pain that travels to your back is something to take seriously and get assessed urgently. The medicine is not licensed for use in pregnancy, while breastfeeding, or if you are actively trying to conceive, and it is not licensed for under-18s. If you have multiple sclerosis and are considering treatment, our page on how MS and Wegovy interact addresses the specific clinical considerations worth discussing with your prescriber. Those living in Northern Ireland can also find region-specific information about accessing Wegovy in Northern Ireland, where commissioning arrangements differ from both Scotland and England.

Wegovy is often discussed alongside semaglutide more broadly; our page on how semaglutide works explains the mechanism in more detail. If you have a specific health condition you are wondering about in relation to treatment, our FAQs cover a range of clinical questions. Our clinical team's background and approach is outlined on the clinical team page if you want to understand who reviews your consultation.

For anyone who has decided private treatment is the right route, you can start your free consultation today. It takes a few minutes, and a prescriber will review your answers the same day.